Amyotrophic Lateral Sclerosis
📧 Sign up to get email alerts when something new happens for Amyotrophic Lateral Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-08-22Clinical Trial Update: Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS). [Phase 2]
Phase 2 clinical trial assessing safety and tolerability of Triumeq in patients with amyotrophic lateral sclerosis (ALS) has completed.
-
EMA withdrawal · 2019-08-14EMA Application withdrawn: Radicava (edaravone) — Mitsubishi Tanabe Pharma GmbH
European Medicines Agency status update indicating withdrawal of the Radicava (edaravone) application by Mitsubishi Tanabe Pharma GmbH for a…
-
CLINICAL_TRIALS trial_result · 2019-07-31Clinical Trial Update: Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation [NA]
A completed clinical trial investigated early treatment of amyotrophic lateral sclerosis with nutrition and non-invasive positive pressure v…
-
CLINICAL_TRIALS trial_result · 2019-06-04Clinical Trial Update: Effect of MD1003 in Amyotrophic Lateral Sclerosis [Phase 2]
Phase 2 clinical trial update for MD1003 in amyotrophic lateral sclerosis (ALS) has completed recruitment.
-
CLINICAL_TRIALS trial_result · 2019-05-10Clinical Trial Update: A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) [Phase 2]
Phase 2 clinical trial of CK-2017357 in patients with amyotrophic lateral sclerosis has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-05-07Clinical Trial Update: A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) [Phase 2]
Phase 2 trial evaluating multiple dosing of CK-2017357 in patients with amyotrophic lateral sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2019-05-03Clinical Trial Update: Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) [Phase 2]
Phase 2 dose titration study completed to evaluate safety and effects of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS).
-
CLINICAL_TRIALS trial_result · 2019-04-09Clinical Trial Update: Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis (Pilot) [NA]
A completed pilot study evaluating remote pulmonary function testing in individuals with amyotrophic lateral sclerosis (ALS).
-
CLINICAL_TRIALS trial_result · 2019-03-27Clinical Trial Update: Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) [Phase 2, Phase 3]
Clinical trial update evaluating edaravone in patients with amyotrophic lateral sclerosis across Phase 2 and Phase 3 trials.
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS [Phase 3]
A Phase 3 trial evaluating TRO19622 as add-on therapy to riluzole in amyotrophic lateral sclerosis has been completed with results posted in…
-
CLINICAL_TRIALS trial_result · 2019-02-12Clinical Trial Update: Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis [Phase 1, Phase 2]
Clinical trial NCT03828123 completed its Phase 1/2 study of autologous multipotent mesenchymal stromal cells in amyotrophic lateral sclerosi…
-
CLINICAL_TRIALS research · 2019-02-08Clinical Trial Update: Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis [Phase 1, Phase 2]
This document outlines a randomized, double-blind clinical trial evaluating the safety and efficacy of recombinant human erythropoietin in a…
-
CLINICAL_TRIALS research · 2019-01-25Clinical Trial Update: Exposure to Neurotoxins as Risk Factors for ALS
This clinical trial update discusses a study examining exposure to neurotoxins as potential risk factors for developing amyotrophic lateral …
-
CLINICAL_TRIALS research · 2019-01-18Clinical Trial Update: Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS (Part 1)
This update covers the development and evaluation of a smart communication system for patients with amyotrophic lateral sclerosis, including…
-
CLINICAL_TRIALS trial_result · 2019-01-11Clinical Trial Update: Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis [Phase 2, Phase 3]
A Phase II/III randomized, placebo-controlled trial evaluating arimoclomol in SOD1-positive familial amyotrophic lateral sclerosis has been …
-
CLINICAL_TRIALS trial_result · 2019-01-10Clinical Trial Update: Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients. [Phase 1, Phase 2]
Phase 1/2 trial of autologous mesenchymal bone marrow stromal cells secreting neurotrophic factors for amyotrophic lateral sclerosis complet…
-
CLINICAL_TRIALS trial_result · 2018-12-31Clinical Trial Update: Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis [Phase 3]
Phase 3 study of MCI-186 (edaravone) for amyotrophic lateral sclerosis has completed, and results were posted on 2018-12-31.
-
CLINICAL_TRIALS trial_result · 2018-12-26Clinical Trial Update: Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis [NA]
Exploratory biotelemetry study in amyotrophic lateral sclerosis completed; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-12-13Clinical Trial Update: ALS Reversals - Lunasin Regimen [Phase 2]
Phase 2 trial update for a Lunasin regimen in ALS shows completed status with posted results in 2018.
-
FDA approval · 2018-11-15FDA Approved: RADICAVA — Supplemental Application (Shionogi Inc.)
The FDA approved a supplemental application for RADICAVA (edaravone) submitted by Shionogi Inc. The action expands the regulatory approval a…
-
FDA approval · 2018-09-05FDA Approved: TIGLUTIK — Original Application (EDW PHARMA, INC)
FDA approved Tiglutik (riluzole) under an Original Application from Edw Pharma, Inc., adding a riluzole product to treat amyotrophic lateral…
-
FDA approval · 2018-08-17FDA Approved: RADICAVA — Supplemental Application (Shionogi Inc.)
The FDA approved a supplemental NDA for RADICAVA (edaravone) from Shionogi Inc., updating its regulatory status after the supplemental appli…
-
CLINICAL_TRIALS trial_result · 2018-08-07Clinical Trial Update: Neuromuscular Magnetic Stimulation in ALS Patients [Phase 2]
Phase 2 clinical trial evaluating neuromuscular magnetic stimulation in patients with amyotrophic lateral sclerosis has completed.
-
EMA withdrawal · 2018-07-31EMA Refused: Alsitek (Masitinib mesilate) — AB Science
The EMA refused approval for Masitinib mesilate (Alsitek) for amyotrophic lateral sclerosis.
-
CLINICAL_TRIALS research · 2018-07-30Clinical Trial Update: Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS [NA]
An update on a clinical trial evaluating a music therapy protocol aimed at supporting bulbar and respiratory functions in people with amyotr…